Hint mode is switched on Switch off
For swift navigation between sections

Adaptive Biotechnologies
LEI 549300ZTF7OT1FW66Q96

PDF download

Choose all Reset all
Download Cancel
Organization name
Adaptive Biotechnologies Corporation
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
300 mln USD
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Unlock data Watch full tour

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Adaptive Biotechnologies is a commercial-stage biotech company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease.

Awards

News

24/07/2026 Adaptive Biotechnologies: Results Of Operations And Financial Condition, Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Financial Statements And Exhibits
23/06/2026 New issue: Adaptive Biotechnologies issued bonds in the amount of USD 300 mln maturing in 2031
15/06/2026 Adaptive Biotechnologies: Other Events, Financial Statements And Exhibits
15/06/2026 Adaptive Biotechnologies: Entry Into A Material Definitive Agreement, Termination Of Material Definitive Agreement, Creation Of A Direct Financial Obligation Or An Obligation Under An, Unregistered Sales Of Equity Securities, Other Events, Financial Statements And Exhibits
18/04/2026 Adaptive Biotechnologies Corporation (NASDAQ: ADPT) Q1 2026 Earnings Preview: Analyzing Financial Health and Market Performance
All organization news

Documentation

IFRS/US GAAP reports

2026
I q eng
2025
I q eng
II q eng
III q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
II q eng
III q eng
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Latest issues

Show all

Public debt by currencies

Show more Hide

Codes

  • LEI
    549300ZTF7OT1FW66Q96
  • SIC
    2836 BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
  • NACE
    *** ***
  • NAICS
    *** ***
  • CIK
    0001478320
  • EIN
    27-0907024
Registration is required to get access.